Yaniv Yechiel

Dr. Yaniv Yechiel


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2024 in PET Clinics
Verified
Journal Article
Closed access
YYYaniv Yechiel
Yaniv Yechiel
ACAlexandre Chicheportiche
Alexandre Chicheportiche
ZKZohar Keidar
Zohar Keidar
SBSimona Ben-Haim
Simona Ben-Haim

22 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LSLital Sharvit
Lital Sharvit
RBRinat Bar-Shalom
Rinat Bar-Shalom
NANaiel Azzam
Naiel Azzam
YYYaniv Yechiel
Yaniv Yechiel
SWSolomon Wasser
Solomon Wasser
Fuad FaresFuad Fares
Fuad Fares
Pancreatic cancer is a highly lethal disease with limited options for effective therapy and the lowest survival rate of all cancer forms. Therefore, a new, effective strategy for cancer treatment is in need. Previously, we found that a culture liquid extract of Cyathus striatus (CS) has a potent antitumor activity. In the present study, we aimed to investigate the effects of Cyathus striatus extract (CSE) on the growth of pancreatic cancer cells, both in vitro and in vivo. The proliferation assay (XTT), cell cycle analysis, Annexin/PI staining and TUNEL assay confirmed the inhibition of cell growth and induction of apoptosis by CSE. A Western blot analysis demonstrated the involvement of both the extrinsic and intrinsic apoptosis pathways. In addition, a RNAseq analysis revealed the involvement of the MAPK and P53 signaling pathways and pointed toward endoplasmic reticulum stress induced apoptosis. The anticancer activity of the CSE was also demonstrated in mice harboring pancreatic cancer cell line-derived tumor xenografts when CSE was given for 5 weeks by weekly IV injections. Our findings suggest that CSE could potentially be useful as a new strategy for treating pancreatic cancer.

6 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YYYaniv Yechiel
Yaniv Yechiel
YOYaly Orr
Yaly Orr
KGKonstantin Gurevich
Konstantin Gurevich
RGRonit Gill
Ronit Gill
ZKZohar Keidar
Zohar Keidar
(1) Purpose: Recent studies indicate that advanced imaging parameters such as prostate PSMA tumor volume may have a value in predicting response to treatment of castration-resistant prostate cancer patients. In this study, we examine whether a relationship can be found between advanced imaging parameters such as prostate PSMA-TV and the presence of metastatic disease in newly diagnosed prostate cancer patients undergoing PSMA-PET/CT for staging purposes; (2) Methods: We retrospectively analyzed PET/CT studies of 91 patients with newly diagnosed prostate cancer. Prostate PSMA-TV was measured using the MIRADA-XD software. PET/CT results were recorded, as well as additional clinical parameters such as the Gleason score, etc.; (3) Results: Prostate PSMA-TV measurements were found to be able to significantly differentiate metastatic from the non-metastatic patient groups (13.7 vs. 5.5, p-value < 0.05). Overall, 54% percent of patients with levels of over 8.1 PSMA-TV had metastatic lesions found on their PSMA-PET/CT. A model based on this cutoff attained a sensitivity of 80%, a specificity of 68.3%, and a negative predictive value of 93.5% for identifying metastatic disease. Another bin model was found statistically capable of assessing the likelihood of the presence of metastatic disease with a p-value of 0.001; (4) Conclusions: Prostate PSMA-TV measurement has the potential to predict the presence of metastatic disease at staging and thus may impact further treatment decision and patient management.

12 October 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
YYYaniv Yechiel
Yaniv Yechiel
ZKZohar Keidar
Zohar Keidar
MWMichal Weiler-Sagie
Michal Weiler-Sagie